Article info
PDFClinical and epidemiological research
Extended report
Effects of golimumab, an anti-tumour necrosis factor-α human monoclonal antibody, on lipids and markers of inflammation
- Correspondence to Bruce W Kirkham, Rheumatology Department, Guy's and St Thomas’ NHS Foundation Trust, London SE1 9RT, UK; bruce.kirkham{at}gstt.nhs.uk
Citation
Effects of golimumab, an anti-tumour necrosis factor-α human monoclonal antibody, on lipids and markers of inflammation
Publication history
- Received May 25, 2012
- Revised October 31, 2012
- Accepted December 2, 2012
- First published January 7, 2013.
Online issue publication
October 25, 2017
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/